A detailed history of Ameritas Investment Partners, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 1,777 shares of MDGL stock, worth $617,418. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,777
Previous 1,719 3.37%
Holding current value
$617,418
Previous $481,000 21.62%
% of portfolio
0.01%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$212.22 - $292.96 $12,308 - $16,991
58 Added 3.37%
1,777 $377,000
Q2 2024

Aug 13, 2024

BUY
$193.33 - $291.99 $46,979 - $70,953
243 Added 16.46%
1,719 $481,000
Q1 2024

May 13, 2024

SELL
$171.37 - $283.23 $9,596 - $15,860
-56 Reduced 3.66%
1,476 $394,000
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $21,551 - $42,446
179 Added 13.23%
1,532 $354,000
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $33,297 - $51,477
228 Added 20.27%
1,353 $197,000
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $27,523 - $42,120
135 Added 13.64%
1,125 $259,000
Q1 2023

May 10, 2023

BUY
$231.06 - $307.08 $11,553 - $15,354
50 Added 5.32%
990 $239,000
Q4 2022

Feb 13, 2023

BUY
$58.39 - $296.54 $2,919 - $14,827
50 Added 5.62%
940 $272,000
Q2 2021

Aug 06, 2021

BUY
$97.2 - $137.59 $10,011 - $14,171
103 Added 13.09%
890 $87,000
Q2 2020

Aug 05, 2020

BUY
$60.13 - $125.71 $6,013 - $12,571
100 Added 14.56%
787 $89,000
Q4 2019

Feb 13, 2020

BUY
$84.28 - $118.5 $7,500 - $10,546
89 Added 14.88%
687 $63,000
Q3 2018

Nov 13, 2018

BUY
$207.3 - $300.31 $17,827 - $25,826
86 Added 16.8%
598 $128,000
Q2 2018

Aug 13, 2018

BUY
$101.55 - $313.9 $15,943 - $49,282
157 Added 44.23%
512 $143,000
Q2 2017

Aug 15, 2017

BUY
N/A
355
355 $6,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.